HI
REVB icon

Harbour Investments’s Revelation Biosciences REVB Stock Holding History

Harbour Investments’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42 Hold
41
– – ﹤0.01% 4685
2026
Q1 		$49 Buy
+41
New +$79 ﹤0.01% 4580

Other funds holding REVB

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Harbour Investments's REVB Position: Q2 2026 in Review

Harbour Investments held its Revelation Biosciences (REVB) position steady in Q2 2026 at 41 shares worth $42. The position accounts for ﹤0.01% of the portfolio, ranked #4685.

Harbour Investments first reported a position in REVB in Q1 2026 and has held it in 2 quarters since. The position peaked at $49 in Q1 2026. 12 funds tracked by Wall St. Rank hold REVB as of Q2 2026.

  • Harbour Investments held 41 shares of Revelation Biosciences worth $42 as of Q2 2026.
  • Harbour Investments left its Revelation Biosciences share count unchanged in Q2 2026.
  • Revelation Biosciences made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4685 holding.
  • Harbour Investments first reported a position in Revelation Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Harbour Investments's Revelation Biosciences position peaked at $49 in Q1 2026.
  • 12 funds tracked by Wall St. Rank held Revelation Biosciences as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.